Replies to post #129783 on Biotech Values

[zipjet]

At this early stage MNTA's attorneys must go for the case they think they have the best chance of making to the judge.

Once discovery is done, it may open other possibilities.

Owning MNTA looks like a very good risk reward play today. Even better for an option writer as the IV likely will jump.

:-)

ij

[DewDiligence]

I agree with Rocky on this point—i.e. in all likelihood, MNTA’s ‘466 patent is no longer in play in the Lovenox patent trial.

Fortunately for MNTA, the immateriality of the ‘466 patent in the ongoing litigation doesn’t matter from a practical standpoint (#msg-68471951).